This is the first of 6 x phase III trials for Kodiak and while the company maybe able to argue poor trial design in this case what could be the killer in the long run is a 3.2% intraoccular inflammation rate compared to Eylea’s 0% in this trial. A high intraoccular inflammation rate of 4% for Novartis’ drug Beovu has been a safety worry which has clearly weighed significantly on the drug’s commercial success.
Ann: Opthea announces establishment of ATM Equity Program, page-17
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.0¢ | 77447 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |